Follow the evidence, wherever it leads
https://www.youtube.com/watch?v=rfyOihhAD4A

Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database

Purpose

To evaluate the difference in mortality,

Patients treated with ivermectin

Patients treated with remdesivir

44 healthcare organizations and 68 million patients from US,

January 1, 2020 and July 11, 2021

Methods & Materials

Retrospectively identified diagnosed adults
Recorded use of ivermectin, but not remdesivir

Recorded use of remdesivir, but not ivermectin

Controlled for, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.

Primary outcome assessed, mortality

Sith significance assessed at p less than 0.05.

Result

41,608 patients who had COVID-19

Treated with ivermectin n = 1,072

Treated with remdesivir n = 40,536

Ivermectin was associated with reduced mortality vs remdesivir
OR 0.308

p less than 0.0001.

Conclusion

Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir.

In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching (Brazil)

https://www.cureus.com/articles/82162...

Background

Ivermectin has demonstrated different mechanisms of action, coronavirus infection and COVID-19-related comorbidities.

Prophylaxis combined with the known safety profile of ivermectin

Study to evaluate the impact of regular ivermectin use on subsequent COVID-19 infection and mortality rates.

Prospective, July 2020 and December 2020

Inviting the entire population of Itajaí to a medical visit to enroll in the program,

ivermectin was offered as an optional treatment to be taken for two consecutive days every 15 days at a dose of 0.2 mg/kg/day.

Study analysis consisted of comparing ivermectin users with non-users using cohorts

Results

223,128 citizens of Itajaí considered

159,561 included in the analysis

113,845 (71.3%) regular ivermectin users

45,716 (23.3%) non-users

Of these

4,311 ivermectin users were infected, (3.7% infection rate)

3,034 non-users (6.6% infection rate)

A 44% reduction in COVID-19 infection rate

Risk ratio (RR), 0.56

The regular use of ivermectin led to a 68% reduction in COVID-19 mortality

Deaths

25 (0.8%) deaths in the ivermectin group

79 (2.6%) among ivermectin non-users

RR, 0.32

p less than 0.0001

When adjusted for residual variables, reduction in mortality rate was 70%

There was a 56% reduction in hospitalization rate

44 in the ivermectin group

99 in non ivermectin users

After adjustment for residual variables, reduction in hospitalization rate was 67%

p less than 0.0001
Conclusion

In this large study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.